CR20230433A - Nuevo agente de contraste para utilizar en imágenes por resonancia magnética - Google Patents

Nuevo agente de contraste para utilizar en imágenes por resonancia magnética

Info

Publication number
CR20230433A
CR20230433A CR20230433A CR20230433A CR20230433A CR 20230433 A CR20230433 A CR 20230433A CR 20230433 A CR20230433 A CR 20230433A CR 20230433 A CR20230433 A CR 20230433A CR 20230433 A CR20230433 A CR 20230433A
Authority
CR
Costa Rica
Prior art keywords
magnetic resonance
contrast agent
resonance imaging
new contrast
compounds
Prior art date
Application number
CR20230433A
Other languages
English (en)
Inventor
Jessica Lohrke
Olaf Panknin
Thomas Brumby
Gregor Jost
Markus Berger
Thomas Frenzel
Hubertus Pietsch
Sven Wittrock
Simon Anthony Herbert
Claudia Green
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CR20230433A publication Critical patent/CR20230433A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con una nueva clase de compuestos de fórmula general (I), con los complejos de quelato de Gd<sup>3+</sup> de los mismos, con métodos para preparar dichos compuestos, y con el uso de dichos compuestos como agentes de contraste para IRM.
CR20230433A 2021-03-15 2023-09-07 Nuevo agente de contraste para utilizar en imágenes por resonancia magnética CR20230433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21162650.2A EP4059925A1 (en) 2021-03-15 2021-03-15 New contrast agent for use in magnetic resonance imaging
PCT/EP2022/056541 WO2022194777A1 (en) 2021-03-15 2022-03-14 New contrast agent for use in magnetic resonance imaging

Publications (1)

Publication Number Publication Date
CR20230433A true CR20230433A (es) 2023-10-23

Family

ID=74874752

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230433A CR20230433A (es) 2021-03-15 2023-09-07 Nuevo agente de contraste para utilizar en imágenes por resonancia magnética

Country Status (19)

Country Link
US (1) US20240182431A1 (es)
EP (2) EP4059925A1 (es)
JP (1) JP2024512459A (es)
KR (1) KR20230157412A (es)
CN (1) CN116981658A (es)
AR (1) AR126325A1 (es)
AU (1) AU2022236333A1 (es)
BR (1) BR112023017197A2 (es)
CA (1) CA3213386A1 (es)
CL (1) CL2023002723A1 (es)
CO (1) CO2023012137A2 (es)
CR (1) CR20230433A (es)
DO (1) DOP2023000185A (es)
EC (1) ECSP23070062A (es)
IL (1) IL305294A (es)
MX (1) MX2023010737A (es)
PE (1) PE20240821A1 (es)
TW (1) TW202302543A (es)
WO (1) WO2022194777A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210069A1 (en) * 2022-01-11 2023-07-12 Bayer Aktiengesellschaft Synthetic contrast-enhanced ct images
WO2024046831A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046832A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046833A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024052156A1 (de) 2022-09-05 2024-03-14 Bayer Aktiengesellschaft Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
EP4336204A1 (de) 2022-09-07 2024-03-13 Bayer AG Beschleunigen von mrt-untersuchungen der leber
EP4335462A1 (en) * 2022-09-09 2024-03-13 Bayer AG Contrast agents for use in diagnostic computed tomography imaging
WO2024083466A1 (de) 2022-10-17 2024-04-25 Bayer Aktiengesellschaft Automatisches analysieren von radiologischen aufnahmen
EP4369353A1 (de) 2022-11-12 2024-05-15 Bayer Aktiengesellschaft Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4369285A1 (de) 2022-11-12 2024-05-15 Bayer AG Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4375919A1 (de) 2022-11-25 2024-05-29 Bayer AG Erzeugen von kontrastverstärkten synthetischen radiologischen aufnahmen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
DE3922005A1 (de) 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
GB9407435D0 (en) 1994-04-14 1994-06-08 Nycomed Salutar Inc Compounds
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
IT1293778B1 (it) 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
AU2001259575A1 (en) 2000-05-04 2001-11-12 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005033902B3 (de) 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
US9693828B2 (en) 2011-12-05 2017-07-04 Bracco Imaging S.P.A. Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation in MRI analysis
CA3137963A1 (en) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents

Also Published As

Publication number Publication date
US20240182431A1 (en) 2024-06-06
EP4308551A1 (en) 2024-01-24
JP2024512459A (ja) 2024-03-19
BR112023017197A2 (pt) 2023-09-26
ECSP23070062A (es) 2023-10-31
WO2022194777A1 (en) 2022-09-22
CN116981658A (zh) 2023-10-31
IL305294A (en) 2023-10-01
DOP2023000185A (es) 2023-10-15
AR126325A1 (es) 2023-10-04
PE20240821A1 (es) 2024-04-18
KR20230157412A (ko) 2023-11-16
AU2022236333A1 (en) 2023-08-31
CO2023012137A2 (es) 2023-09-29
MX2023010737A (es) 2023-09-20
TW202302543A (zh) 2023-01-16
CL2023002723A1 (es) 2024-01-26
CA3213386A1 (en) 2022-09-22
EP4059925A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
CR20230433A (es) Nuevo agente de contraste para utilizar en imágenes por resonancia magnética
AR104897A1 (es) Compuestos de quelatos de gadolinio para usar en imágenes de resonancia magnética
PE20160678A1 (es) Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata
CO6501196A2 (es) Compuestos antiproliferativos, cojugados de los mismos, procedimientos para éstos y uso de los mismos
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
BRPI0617151B8 (pt) composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
UY37500A (es) Nuevos compuestos de quelato de gadolinio con alta relaxividad para usar en la obtencion de imagenes por resonancia magnetica
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
MX2013009690A (es) Composiciones para teñido oxidativo que comprenden un 1-hextil/heptil-4,5-diaminopirazol y una benceno-1,-3-diamina y derivados de estos.
BR112018076389A2 (pt) composto, método para preparação de um composto, e, composição farmacêutica.
CO2021012375A2 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
JP2015509966A5 (es)
IN2014DN03197A (es)
AR086803A1 (es) Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras
ES2541787B1 (es) Compuestos y composiciones que comprenden nanotubos de carbono y compuestos de formula (I) y su uso como agentes de contraste
PE20211471A1 (es) Formulacion de medios de contraste y proceso para prepararlos
BR112022003242A2 (pt) Composto, composição, e, métodos de formação de imagens, de síntese enantiosseletiva e de produção
AR046212A1 (es) Derivados de 2-fenilbenzofurano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR095353A1 (es) Compuesto
AR120033A1 (es) Antagonista radiomarcado de grpr para uso como agente teragnóstico
CO2021009388A2 (es) Nanopartícula, agente de contraste para formación de imágenes por resonancia magnética que comprende la misma y un compuesto de ligando zwitteriónico
BR112023008166A2 (pt) Composições de lnp compreendendo rna e métodos para preparar, armazenar e usar as mesmas
UY30581A1 (es) Agentes que comprenden compuestos marcados con 18f y métodos relacionados
DOP2009000036A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados